Alexion Pharmaceuticalsis opening an office and laboratory facility in Dublin in conjunction with the company’s decision to establish a global supply chain facility in Ireland. Alexion has begun recruiting approximately 50 employees for a range of initial positions in its supply chain, quality assurance, quality control and logistics functions to open by yearend.

Alexion’s new supply chain and staff are expected to begin supplying Soliris (eculizumab) to patients with PNH and aHUS, two life-threatening ultra-rare disorders, by the end of 2013.  The company’s workforce will also manage the supply of additional Alexion medicines to patients following regulatory approvals for a series of anticipated launches of new therapies over the next several years.